Inhaler-Based Immunotherapy for Lung Cancer

Lung cancer is among the most lethal malignancies worldwide, with limited therapeutic success despite advancements in immunotherapy. Immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1 pathways, have marked a paradigm shift in cancer treatment. However, their efficacy in lung cancer remains suboptimal due to the immunosuppressive tumor microenvironment (TME), T cell exhaustion, and tumor heterogeneity. Additionally, the heterogeneity of lung cancer introduces variability in PD-L1 expression, further complicating therapeutic outcomes. In a recent study reported in Science Advances, researchers from the Fourth Hospital of Harbin Medical University (China) have reported a novel approach using PFCE-C25 nanoemulsions (NEs), which has shown promising results in targeting the complex immunosuppressive tumor microenvironment (TME) and overcoming these limitations of current lung cancer therapies.

Structure and Function of PFCE-C25 NEs

PFCE-C25 NEs integrate a C25 cyclic peptide, targeting LAG-3, with perfluoro-15-crown-5-ether (PFCE), a biocompatible nanoemulsion core. The C25 peptide disrupts LAG-3’s inhibitory signaling by binding its MHC-II interaction site, reactivating CD8+ and CD4+ T cells. PFCE enhances drug delivery and imaging capabilities, enabling precise tumor localization via 19F-MRI. The nanoemulsions are optimized for nebulization, facilitating efficient delivery to lung tumors and tumor-draining lymph nodes (TDLNs), where they promote DC maturation and robust immune responses.

Mechanisms of Action

PFCE-C25 NEs work through several mechanisms to enhance anti-tumor immunity:

  • LAG-3 Inhibition: By targeting LAG-3, PFCE-C25 NEs disrupt its interaction with MHC-II, restoring T cell functionality and reducing immune suppression
  • Enhanced T Cell Activation: Flow cytometry revealed significant increases in CD8+ IFN-γ+ and CD4+ IFN-γ+ T cells in TDLNs, indicating improved T cell activation.
  • Dendritic Cell (DC) Maturation: PFCE-C25 NEs promote DC maturation in TDLNs, facilitating more effective antigen presentation and T cell priming.
  • Regulatory T Cell (Treg) Suppression: By inhibiting LAG-3, PFCE-C25 NEs limit the activity of immunosuppressive Tregs within the TME.

LAG-3 as a Target in Immunotherapy

Lymphocyte activation gene 3 (LAG-3) has emerged as a critical immune checkpoint. By negatively regulating T cell activity, LAG-3 fosters immune evasion in tumors. Its expression on multiple immune cells, including Tregs and dendritic cells (DCs), underscores its role in maintaining the immunosuppressive TME. High LAG-3 expression correlates with increased malignancy and poorer prognosis, making it a compelling target. Dual blockade of LAG-3 and PD-1/PD-L1 pathways has shown promise in restoring T cell function and enhancing antitumor immunity.

Pulmonary Delivery: An Innovative Therapeutic Avenue

Pulmonary drug delivery offers unique advantages over systemic administration. By directly targeting lung tissues and associated lymph nodes, pulmonary delivery ensures high drug concentrations at the tumor site while minimizing systemic exposure. This route bypasses hepatic first-pass metabolism, enhances bioavailability, and reduces off-target effects. Innovative drug carriers, such as PFCE nanoemulsions, enhance the precision and efficacy of pulmonary therapies. PFCE-C25 NEs, specifically designed for inhalation, exploit the anatomical and physiological advantages of the lungs, including their large surface area, rich vasculature, and thin epithelial barriers.

Efficacy in Preclinical Models

PFCE-C25 NEs have demonstrated remarkable efficacy in preclinical lung cancer models:

  • Tumor Growth Inhibition: PFCE-C25 NEs exert their effects through immune activation rather than direct cytotoxicity. They enhance T cell priming, increase interferon-gamma (IFN-γ) production, and stimulate DC maturation. These immune-modulatory properties significantly remodel the TME, reducing Treg-mediated suppression and fostering antitumor activity.
  • Prolonged Survival: In metastatic models, PFCE-C25 NEs demonstrated superior tumor inhibition and prolonged survival compared to conventional systemic therapies, emphasizing their therapeutic potential.
  • Induction of Immune Memory: A hallmark of PFCE-C25 NEs is their ability to induce durable immune memory. Treated mice displayed elevated levels of memory T cells and complete resistance to secondary tumor challenges. This immune surveillance mechanism ensures long-term tumor control, highlighting the potential of PFCE-C25 NEs to provide sustained antitumor immunity.
  • Abscopal Effects: Remarkably, PFCE-C25 NEs elicited systemic antitumor responses, suppressing both local and distant tumor growth. This abscopal effect underscores their capability to activate immune cells in TDLNs, which then circulate to target metastatic sites. The observed systemic effects position PFCE-C25 NEs as a powerful tool for managing metastatic disease.

Distribution, Biocompatibility, and Safety Profiling

PFCE-C25 NEs exhibit optimal lung-specific localization and prolonged retention. Their uniform distribution within the alveolar spaces and tumor tissues ensures effective targeting. Importantly, they demonstrated excellent biocompatibility, with no adverse effects on major organs, hematological parameters, or liver and kidney function. This safety profile, combined with their non-cytotoxic mode of action, underscores the potential of PFCE-C25 NEs as a clinically viable therapy.

Conclusion

PFCE-C25 NEs represent a groundbreaking approach to lung cancer immunotherapy. By combining targeted LAG-3 inhibition with efficient pulmonary delivery, this innovative treatment offers a potent, safe, and potentially more effective alternative to current checkpoint inhibitors. The ability to induce both local and systemic anti-tumor responses, coupled with excellent biocompatibility, positions PFCE-C25 NEs as a promising candidate for clinical development in the treatment of lung cancer and potentially other malignancies.

Reference

Respiratory delivery of single low-dose nebulized PFCE-C25 NEs for lymphatic transport and durable stimulation of antitumor immunity in lung cancer | Science Advances

Additional information

Cell-based and Preclinical Assays Used in Developing an Inhaler-Based Immunotherapy for Lung Cancer

• Cell-Based Assay for Targeting LAG-3+ Cells
Purpose & Method: Validate the specific targeting of the nebulized immunotherapy drug (PFCE-C25 NEs) to LAG-3+ cells. Fluorescence imaging and confocal microscopy demonstrated PFCE-C25 NEs binding to LAG-3+ CD8+ T cells. Blocking antibodies were used as negative controls.

• Human PBMC (hPBMC) Assay
Purpose & Method: Assess the immune activation potential of the inhaled nano-immunotherapy drug. PBMCs were stimulated with PMA/ionomycin and incubated with PFCE-C25 NEs. Flow cytometry https://www.marinbio.com/services/flow-cytometry/ quantified IFN-γ production in T cell subsets to measure activation.

• Human TDLN (hTDLN) Assay
Purpose & Method: Investigate the interaction of PFCE-C25 NEs with human tumor-draining lymph nodes (TDLNs) to evaluate clinical relevance. Fresh hTDLN samples were incubated with PFCE-C25 NEs, followed by 19F-MRI, fluorescence imaging, and histological analysis.

• 19F-MRI Studies
Purpose & Method: Visualize the localization and retention of PFCE-C25 NEs. In vitro and in vivo studies confirmed nanoemulsion targeting of tumors and TDLNs at various concentrations using 19F-MRI.

• Lung, Tumor, and TDLN Retention Studies
Purpose & Method: Validate lung-specific distribution and retention. Fluorescently labeled PFCE-C25 NEs were nebulized into LLC mouse models, with confocal microscopy tracking their localization.

• In Situ Lung Cancer Mouse Models
Purpose & Method: Mimic human lung cancer progression for preclinical testing. Orthotopic lung cancer models were established using LLC, CMT167, and NCI-H460 cells. Humanized mouse models with PBMCs were generated for translational relevance.

• In Vivo Treatment and Efficacy Monitoring
Purpose & Method: Compare the therapeutic potential of PFCE-C25 NEs with controls. Groups were treated with PFCE-C25 NEs, C25 peptide, LAG-3 antibody, or PBS. Tumor growth and survival were monitored via MRI and histological analysis.

• Flow Cytometry Validation
Purpose & Method: Quantify immune cell infiltration and activation. T cell and DC populations, IFN-γ expression, and Treg proportions in tumors and TDLNs were analyzed.

• DC Maturation Testing
Purpose & Method: Evaluate the role of PFCE-C25 NEs in promoting DC maturation. Immunofluorescence and flow cytometry measured DC active n markers (CD80, CD86) in TDLNs.

• Tumor-Specific Immune Memory Assay 
Purpose & Method: Verify the development of durable antitumor immunity. Mice cured with PFCE-C25 NEs were rechallenged with tumor cells, and T cell memory subsets (TCM, TEM) were analyzed via flow cytometry 

• Cytokine Evaluation
Purpose & Method: Correlate cytokine production with immune activation. ELISA quantified IL-6, IL-12, TNF-α, and IFN-γ concentrations in tumors and sera.

• Biological Safety Testing
Purpose & Method: Confirm the safety and biocompatibility of PFCE-C25 NEs. Histological analysis of major organs and blood biochemical tests demonstrated minimal toxicity.

• Biodistribution Study
Purpose & Method: Ensure targeted delivery with minimal off-target effects. Fluorescence imaging and 19F-NMR quantified PFCE-C25 NE concentrations in tumors, lungs, and other organs over time.

• Cell Cytotoxicity Assay
Purpose & Method: Confirm immune-mediated antitumor effects without direct cytotoxicity. MTT assays indicated no direct toxic effects on cancer cells, supporting an immune activation mechanism.

These methods collectively validated the synthesis, targeting, immune activation, safety, and therapeutic efficacy of PFCE-C25 NEs in preclinical lung cancer models.

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories